Reviews/Giant Cell Arteritis/Temporal artery halo sign diagnostic
Imaging · GCA-IMG-01 · v2
Across several independent patient groups, a bright ring (the halo sign) seen on ultrasound of the temporal artery picks out most people who turn out to have giant cell arteritis, and trained specialists agree well on when they see it [1][5][6][7][2][3]. But the sign is not unique to the disease: it also appears in other conditions, so a positive result is not proof on its own [4]. How well it performs also shifts with the patient's cardiovascular risk, with prior steroid treatment, and with how experienced the operator is [3][7][10][13]. The panel treated it as a strong, validated pointer that supports the diagnosis rather than a test that settles it by itself. That is why the record frames the halo sign as a key contributor to, not an independent arbiter of, a GCA diagnosis.
Multiple primary diagnostic-accuracy cohorts find the halo sign and halo-based scores carry substantial information for a clinical diagnosis of GCA: ultrasound sensitivity 63% and specificity 79% against biopsy and clinical diagnosis in [6], halo-count sensitivity 76.7% and specificity 97.2% in [5], a Halo Score ROC area of 0.835 in [7], and ultrasound sensitivity 86.5% with specificity 74.3% in [13]. The sign is also read reliably by trained sonographers, with inter-rater and intra-rater kappa values of 0.83-0.98 in [2] and excellent agreement after a standardised training programme in [8]. However [4] documents the halo sign in 14 of 305 (4.6%) patients without GCA, including PMR, atherosclerosis and lymphoma. Performance is conditional: specificity drops in high cardiovascular-risk patients [7][13] and the sign is less frequent after prior corticosteroid therapy [10]. The contested point: The division is over whether the sign 'diagnoses' GCA or merely supports the diagnosis. The accuracy cohorts [1][5][6][7][13] show strong but imperfect performance, while [4] shows the sign is not unique to GCA and [3] shows accuracy collapses without expert operators, so the record settles on strong support rather than an independent diagnostic.
All 13 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Giant Cell Arteritis, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
Incorporation bias: the reference standard is clinician diagnosis at 6 months, which is itself informed by the ultrasound result [1][6][7], inflating apparent accuracy.
Imperfect specificity: [4] shows the halo sign in PMR, atherosclerosis, lymphoma, GPA and others, so the sign does not uniquely diagnose GCA.
Where it remains uncertain. The sign appears in non-GCA conditions in 4.6% of halo-positive patients [4] and its accuracy falls with high cardiovascular risk [7][13] and prior corticosteroids [10], so a positive result supports rather than proves GCA.
Aleatory
Accuracy estimates come from modest cohorts (N=78 [6], N=79 [5], N=157 [7]) so sensitivity and specificity vary with chance sampling of each centre's patients.
Epistemic
The 6-month clinical reference standard is informed by the ultrasound itself [1][6][7], so true accuracy is not cleanly measured and could be lower.
Inferential
[2][3][8] show the sign can be read consistently, not that it diagnoses GCA, so they cannot carry the diagnostic claim on their own.
The load-bearing papers from a corpus of 13, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Prospective cohort (N=89): establishes moderate, not perfect, diagnostic accuracy of halo-based scoring.
“Halo counts and Halo Scores showed moderate diagnostic accuracy for a clinical diagnosis of GCA.”
Panel auditInternal validity: medium · scope of inference: Patients suspected of GCA undergoing temporal and axillary ultrasound prior to biopsy; speaks to quantified halo scoring, not the bare halo sign.Key limitations: accuracy only 'moderate' · no sens/spec figures in abstract · single-cohort
Real-world cohort (N=79): confirms good sensitivity and excellent specificity of halo-based scores.
“All three scores display good sensitivity and excellent specificity, although the cutoff was slightly different than proposed.”
Panel auditInternal validity: medium · scope of inference: First-visit patients suspected of GCA at one vasculitis clinic; applies to quantitative halo scores rather than the unquantified halo sign.Key limitations: retrospective single-centre · cut-offs re-derived in-sample · small sample
Head-to-head vs biopsy (N=78): quantifies moderate sensitivity and sub-biopsy specificity of US.
“ultrasound a sensitivity of 63% (45-79%) and a specificity of 79% (64-94%)”
Panel auditInternal validity: medium · scope of inference: Patients suspected of GCA assessed shortly after starting steroids; speaks to ultrasound as first-line versus biopsy.Key limitations: imaging after steroid initiation · modest specificity 79% · single-centre
Documents that the halo sign is not unique to GCA, bounding its specificity.
“Fourteen of the 305 (4.6%) patients included showed presence of the halo sign without final diagnosis of GCA”
Panel auditInternal validity: medium · scope of inference: Patients already showing a halo sign; identifies false-positive causes, bounding but not quantifying specificity of the sign for GCA.Key limitations: retrospective records · halo-positive only (no denominator for specificity) · false-positive rate reported as low 4.6%
4 of 13 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Consistent diagnostic-accuracy evidence supports the halo sign as a key diagnostic test, but incorporation bias, documented false positives and operator/context dependence keep it below the Established band.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Independent reference standard. Apparent accuracy is inflated because the clinical diagnosis incorporates the ultrasound [1][6][7], which is the largest threat to the diagnostic claim. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A prospective cohort in which the final GCA diagnosis is adjudicated blind to the ultrasound result, or against a composite standard that excludes it.
Open question: What is the halo sign's diagnostic accuracy against a reference standard that does not incorporate the ultrasound result? Why it is still open: Every accuracy cohort uses a 6-month clinical diagnosis informed by the ultrasound [1][6][7], leaving true accuracy unmeasured.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19